Topical Collection "Insulin Resistance in the 2020's"

A topical collection in Metabolites (ISSN 2218-1989). This collection belongs to the section "Endocrinology and Clinical Metabolic Research".


Dr. Amedeo Lonardo
Website1 Website2
Guest Editor
Section Editor
Azienda Ospedaliero-Universitaria di Modena, Modena, Italy
Interests: NAFLD-MAFLD; cirrhosis; hepatocellular carcinoma; metabolic syndrome; insulin resistance; sex differences
Special Issues and Collections in MDPI journals

Topical Collection Information

Dear Colleagues,

Insulin resistance (IR) is defined as the impaired intracellular signaling of endogenous and exogenous insulin. IR is a major key player in those metabolic derangements that characterize physiological states (e.g., puberty and pregnancy) and pathological conditions (e.g., diabesity and metabolic syndrome). In particular, IR is a key determinant of a wide-ranging spectrum of diseases spanning cardio-nephro-metabolic disorders to the end-stage failure of such vital organs as the heart, the kidney and the liver, and also certain types of cancer such as, for example, gastrointestinal and breast cancers.

The obesogenic world in which a large part of the human population resides is a recognized facilitator of IR development and progression. However, genetic traits may predispose to the specific array of complications and manifestations that typically characterize patients. Therefore, owing to its epidemiological and clinical burden, IR is an attractive topic both in basic and clinical research. Interest in molecular mechanisms, translational approaches and strong interdisciplinarity characterize IR research, which brings together investigator-driven studies as well as industry-sponsored investigations.

The aim of this Topic Collection is to publish high-quality review and research papers in IR. We make a call for well-written review articles and original papers spanning the areas of glucose metabolism, lipid metabolism, obesity, cardiovascular and fatty liver disease. The scope of this Topic Collection includes, but is not limited to: homeostatic model assessment, insulin sensitivity, Type 2 diabetes, polycystic ovary syndrome, nonalcoholic fatty liver disease, oxidative stress, inflammation, beta cell function and hepatic steatosis.

Dr. Amedeo Lonardo
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the collection website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Metabolites is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • abdominal obesity
  • adipokines
  • adipose tissue
  • adiposopathy
  • aldosteronism
  • Alzheimer’s disease
  • android obesity
  • apolipoprotein
  • androgens
  • arterial hypertension
  • atherogenic dyslipidemia
  • atherosclerosis
  • beta cell function
  • beta cell secretion
  • bile acids
  • biomarkers
  • body mass index
  • cancer
  • cardiovascular disease
  • cell biology
  • childhood obesity
  • chronic kidney disease
  • cardiovascular risk
  • coronary artery disease
  • COVID-19
  • diabetes
  • diabetic foot
  • diagnosis
  • dyslipidemia
  • drug management
  • endoplasmic reticulum stress
  • estrogens
  • extracellular vesicles
  • fertility
  • genetics
  • geriatric medicine
  • gestational diabetes
  • glp-1 receptor agonists
  • glucose (in)tolerance
  • glucose homeostasis
  • glucose metabolism
  • glucose transport
  • gut microbiota
  • growth hormone
  • hepatic steatosis
  • hepatokines
  • high-fat diet
  • histology
  • HIV
  • homeostatic model assessment (HOMA)
  • hyperadrenalism
  • hypercortisolism
  • hyperinsulinemia
  • imaging techniques
  • insulin-like growth factor
  • insulin resistance
  • insulin receptor
  • insulin sensitivity
  • insulin signaling
  • insulin secretion
  • insulin sensitizers
  • lifestyle
  • lipid metabolism
  • lipotoxicity
  • metabolic syndrome
  • metformin
  • molecular biology
  • natural history
  • nonalcoholic fatty liver disease
  • nonalcoholic steatohepatitis
  • oxidative stress
  • pediatric medicine
  • peripheral artery disease
  • personalized medicine
  • polycystic ovary syndrome
  • prediabetes
  • randomized clinical trial
  • SARS-CoV-2
  • type 2 diabetes
  • peroxisome proliferator
  • protein kinase
  • sex differences
  • skeletal muscle
  • thiazolidinediones
  • thyroid
  • viral hepatitis

Published Papers (1 paper)


Open AccessCommentary
What’s Past Is Prologue: History of Nonalcoholic Fatty Liver Disease
Metabolites 2020, 10(10), 397; - 08 Oct 2020
Cited by 1
Since the initial descriptions in the early 1980s by Dr. Ludwig et al. and Drs. Schaffner and Thaler, who firstly coined the terms nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD), this liver disease has become a global health problem worldwide, causing [...] Read more.
Since the initial descriptions in the early 1980s by Dr. Ludwig et al. and Drs. Schaffner and Thaler, who firstly coined the terms nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD), this liver disease has become a global health problem worldwide, causing considerable liver-related and extra-hepatic morbidity and mortality. Based on pathophysiological insights gained from the past decades, it has been clearly established that NAFLD is a metabolic liver disease whose etiology and pathogenesis extends beyond the liver and that NAFLD has important clinical implications, especially in terms of an increased risk of developing both cardiovascular disease (which represents the leading cause of death in this patient population) and other extra-hepatic manifestations, such as type 2 diabetes mellitus, chronic kidney disease, and some extra-hepatic cancers. The aim of this brief commentary is to discuss a recent review article written by Dr. Lonardo and colleagues, who raised awareness of the history of NAFLD. Since “What’s past is prologue”, I believe that this review article focusing on the history of NAFLD may contribute to better understanding the disease itself, as well as to anticipating the lines of the future clinical and pharmacological research of this common and burdensome liver disease. Full article
Show Figures

Figure 1

Back to TopTop